FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283383886> ?p ?o ?g. }

• W4283383886 endingPage "1863" @default.
• W4283383886 startingPage "1862" @default.
• W4283383886 abstract "Background: Multiple myeloma (MM) is a common hematological malignant neoplasm and it is primarily a disease of the elderly. Development of newer therapeutic agents and improving supportive care over the last decades has significantly improved outcome of MM in younger patients. However, most studies suggest that improvements are marginal in elderly patients. Aims: The aim of the study is to report the clinical, paraclinical and therapeutic features of the elderly multiple myeloma (age >65 years) in our center. Methods: We retrospectively reviewed data of patients aged over 65 years diagnosed with MM and treated at the hematology department of Hedi Chaker Hospital Sfax between January 2012 and December 2019. Response to treatment is evaluated according to the International Myeloma Working Group (IMWG). these patients are considered ineligible for autologous stem cell transplantation (ASCT). The induction regimen is based on the combination melphalan-prednisone-thalidomide (MPT) or melphalan-prednisone (MP). Clinical outcomes included: reason for treatment discontinuation, overall response rate (ORR), overall survival (OS), progression-free survival (PFS), and adverse events (AE). Results: A total of 40 patients (sex ratio M/F=1.35) were included in our study. Median age was 73 years [65-93 years]. 10 patients (25%) aged ≥80 years. Performance status (PS) was ≥2 in 29 patients (73%). sixty percent of the cases had at least one comorbidity. The median Charlson Comorbidity Index (CCI) was 4 [2–7]. Bone pain was the most common presenting complaint observed in 65% of the cases. Monoclonal IgG was the predominant protein M type’s (70%). According to the Durie-Salmon Staging System, IIIA was the main stage noted in 64% of the cases followed by IIIB in 23% of the cases. MPT and MP regimens were received in 57% and 17/40 respectively. ORR was 23%, including, VGPR 5 %, and PR 18%. None of the cases acheived complete remission. Stable disease occurred in 30 % and progressive disease in 7.5%. The remain cases were non evaluable (15/40). Treatment was discontinued in 14 cases (35%) after a median of 2 courses due to either progression or toxicity. Main adverse events were infectious in 25% (10 cases) and hematological in 22% (9 patients). Median Follow up was 77 months. Median survival was 24 months. OS and PFS were 47% and 44% at 2 years and 27% and 23% at 5 years respectively. Summary/Conclusion: Despite the fact that one third of our patients had no comorbidity, MPT and MP regimens in our study had insufficient results and correlated with a lower ORR and median survival comparatively to the literature (24 vs 48 months). It can be explained by the low rate of patients receiving Thalidomide. The combination of bortezomib-lenalidomide-dexamethasone for elderly patients may improve our results. In addition, structured frailty assessment is required in order to devise individualized treatment plan able to improve the clinical outcomes and the Quality of life." @default.
• W4283383886 created "2022-06-25" @default.
• W4283383886 creator A5001360263 @default.
• W4283383886 creator A5001702374 @default.
• W4283383886 creator A5009180317 @default.
• W4283383886 creator A5030931728 @default.
• W4283383886 creator A5031025805 @default.
• W4283383886 creator A5034031232 @default.
• W4283383886 creator A5049435131 @default.
• W4283383886 creator A5051956051 @default.
• W4283383886 creator A5059218186 @default.
• W4283383886 creator A5067377366 @default.
• W4283383886 creator A5080327314 @default.
• W4283383886 date "2022-06-01" @default.
• W4283383886 modified "2023-09-26" @default.
• W4283383886 title "PB1990: MULTIPLE MYELOMA IN THE ELDERLY: A MONOCENTRIC EXPERIENCE" @default.
• W4283383886 doi "https://doi.org/10.1097/01.hs9.0000850796.58782.56" @default.
• W4283383886 hasPublicationYear "2022" @default.
• W4283383886 type Work @default.
• W4283383886 citedByCount "0" @default.
• W4283383886 crossrefType "journal-article" @default.
• W4283383886 hasAuthorship W4283383886A5001360263 @default.
• W4283383886 hasAuthorship W4283383886A5001702374 @default.
• W4283383886 hasAuthorship W4283383886A5009180317 @default.
• W4283383886 hasAuthorship W4283383886A5030931728 @default.
• W4283383886 hasAuthorship W4283383886A5031025805 @default.
• W4283383886 hasAuthorship W4283383886A5034031232 @default.
• W4283383886 hasAuthorship W4283383886A5049435131 @default.
• W4283383886 hasAuthorship W4283383886A5051956051 @default.
• W4283383886 hasAuthorship W4283383886A5059218186 @default.
• W4283383886 hasAuthorship W4283383886A5067377366 @default.
• W4283383886 hasAuthorship W4283383886A5080327314 @default.
• W4283383886 hasBestOaLocation W42833838861 @default.
• W4283383886 hasConcept C126322002 @default.
• W4283383886 hasConcept C141071460 @default.
• W4283383886 hasConcept C194409129 @default.
• W4283383886 hasConcept C197934379 @default.
• W4283383886 hasConcept C2776063141 @default.
• W4283383886 hasConcept C2776364478 @default.
• W4283383886 hasConcept C2778684742 @default.
• W4283383886 hasConcept C2778715236 @default.
• W4283383886 hasConcept C2778720950 @default.
• W4283383886 hasConcept C2779050716 @default.
• W4283383886 hasConcept C2779159551 @default.
• W4283383886 hasConcept C2779609412 @default.
• W4283383886 hasConcept C2781413609 @default.
• W4283383886 hasConcept C71924100 @default.
• W4283383886 hasConceptScore W4283383886C126322002 @default.
• W4283383886 hasConceptScore W4283383886C141071460 @default.
• W4283383886 hasConceptScore W4283383886C194409129 @default.
• W4283383886 hasConceptScore W4283383886C197934379 @default.
• W4283383886 hasConceptScore W4283383886C2776063141 @default.
• W4283383886 hasConceptScore W4283383886C2776364478 @default.
• W4283383886 hasConceptScore W4283383886C2778684742 @default.
• W4283383886 hasConceptScore W4283383886C2778715236 @default.
• W4283383886 hasConceptScore W4283383886C2778720950 @default.
• W4283383886 hasConceptScore W4283383886C2779050716 @default.
• W4283383886 hasConceptScore W4283383886C2779159551 @default.
• W4283383886 hasConceptScore W4283383886C2779609412 @default.
• W4283383886 hasConceptScore W4283383886C2781413609 @default.
• W4283383886 hasConceptScore W4283383886C71924100 @default.
• W4283383886 hasLocation W42833838861 @default.
• W4283383886 hasLocation W42833838862 @default.
• W4283383886 hasLocation W42833838863 @default.
• W4283383886 hasOpenAccess W4283383886 @default.
• W4283383886 hasPrimaryLocation W42833838861 @default.
• W4283383886 hasRelatedWork W1576670771 @default.
• W4283383886 hasRelatedWork W1984900639 @default.
• W4283383886 hasRelatedWork W2018729528 @default.
• W4283383886 hasRelatedWork W2025081120 @default.
• W4283383886 hasRelatedWork W2072770520 @default.
• W4283383886 hasRelatedWork W2104897208 @default.
• W4283383886 hasRelatedWork W2127039831 @default.
• W4283383886 hasRelatedWork W2140806332 @default.
• W4283383886 hasRelatedWork W2397153342 @default.
• W4283383886 hasRelatedWork W3031000592 @default.
• W4283383886 hasVolume "6" @default.
• W4283383886 isParatext "false" @default.
• W4283383886 isRetracted "false" @default.
• W4283383886 workType "article" @default.